30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
- Poster presentation
- Open Access
CTS™ immune cell SR for serum free culture and expansion of human T cells
Journal for ImmunoTherapy of Cancer volume 3, Article number: P1 (2015)
The manufacture of a majority of clinical T cell products for immunotherapy applications requires in vitro T cell culture and expansion. Commercialization of T cell manufacturing processes requires reagents that meet regulatory guidelines and ultimately help reduce manufacturing cost of goods. A key component in many T cell culture protocols is human serum, which is expensive and requires extensive testing prior to use for the manufacture of cGMP-compliant T cell therapies. To this end, we have developed a xeno-free serum replacement, CTS™ Immune Cell SR, with defined components that can be used in combination with multiple cell culture media to support in vitro expansion of functionally intact T cells.
T cells activated and expanded with Dynabeads® CD3/CD28 CTSTM and cultured in CTS™ OpTmizer™ T cell Expansion SFM, X-VivoTM 15, or CTS™AIM-V® supplemented with pooled human serum or serum free CTS™ Immune Cell SR showed similar growth kinetics, total fold expansion and transduction efficiency after 2 weeks in culture. Numbers of CD4+ and CD8+ T cells were comparable in cultures expanded with media containing human serum or CTS™ Immune Cell SR. T cells demonstrated efficacy when infused in an in vivo leukemia mouse model. T cell engraftment and leukemia control were similar between mice treated with T cells grown in media containing human serum or CTS™ Immune Cell SR.
These studies demonstrate that human serum may be replaced by a xeno-free formulation in combination with several commonly used T cell culture media to support in vitro expansion and lentiviral transduction of polyclonal T cells. Culturing T cells in CTS™ Immune Cell SR facilitates a favorable culture profile and immune function. Serum free CTS™ Immune Cell SR contains only fully tested human-derived or human recombinant proteins which facilitates supply security for large-scale production of clinical and commercial therapies.
About this article
Cite this article
Okern, G., Varela-Rohena, A., Kuligowski, S. et al. CTS™ immune cell SR for serum free culture and expansion of human T cells. j. immunotherapy cancer 3, P1 (2015). https://doi.org/10.1186/2051-1426-3-S2-P1
- Human Serum
- Serum Free Culture
- Cell Manufacturing
- Serum Replacement
- Regulatory Guideline